We’re pleased to announce that AnHeart is now part of Nuvation Bio. We look forward to working together to bring new cancer therapies to patients in need.

Learn more:shorturl.at/ablIV

We’re excited to announce we’ve entered into an agreement for Nuvation Bio to acquire AnHeart Therapeutics.

We look forward to continuing our work as part of Nuvation Bio to bring new cancer therapies to patients in need of better options.

Learn more: anhearttherapeutics.com/news/press-rel…

Today AnHeart and Innovent announced that China’s NMPA has accepted an NDA for our investigational precision therapy as a first-line treatment for adults with advanced or metastatic ROS1-positive NSCLC who have not been treated with ROS1 TKIs.
anhearttherapeutics.com/news/press-rel…

#lcsm

We had a great #JPM2024 week and hope everyone else did too.

We're feeling energized and inspired and are looking forward to a busy 2024 focused on continued progress developing our pipeline of precision oncology medicines.

#JPM24

We’re excited to be attending #JPM2024 ! We look forward to connecting with industry leaders to discuss the latest innovations in healthcare.

Connect with us onsite to learn more about our pipeline of novel precision therapies for people with cancer.

#JPM24

We are excited to share that our recently accepted NDA in China for our lead investigational precision therapy has been granted Priority Review Designation.

Learn more: shorturl.at/dAQT2

#lcsm #ROS1 #PrecisionOncology

We're excited to announce a collaboration with Foundation Medicine to develop companion diagnostics for our investigational next-generation therapy for ROS1+ NSCLC. We look forward to partnering as we make progress towards bringing a potential new option to patients in need.

We’re excited to announce a NDA for our investigational precision therapy for ROS1+ #NSCLC has been accepted in China - marking our first global regulatory submission for taletrectinib.

Learn more: anhearttherapeutics.com/news/press-rel…

#lungcancer

#InTheNews : On Oct. 31, President Biden proclaimed the month of November to be National Lung Cancer Awareness Month.

Now, more than ever, we're committed to providing new treatments for #ROS1 -positive #NSCLC .

Learn more:
shorturl.at/dhv28

#LCAM #LCSM #PrecisionOncology

It’s Lung Cancer Awareness Month and we’re spreading the word. We’re looking forward to the special GO2 for Lung Cancer Lung Cancer Living Room episode: “Coming Together Globally to Combat Stigma” on November 16.

#LCAM #lcsm #lungcancerawarenessmonth

We are excited to announce the appointment of Guilin Huang as SVP of Development and Amy Muse as VP of U.S. Commercial.

Join us in welcoming Guilin and Amy to our team! shorturl.at/gLOY4

#AnHeart #PrecisionOncology

We are excited to announce that we have entered an exclusive license agreement with Nippon Kayaku to market and distribute our lead investigational therapy, taletrectinib, in Japan.

Learn more: shorturl.at/joBM1

#ROS1 #lcsm

Thank you to #ESMO23 organizers for an inspiring and informative congress!

#ICYMI , we presented positive interim data from our global pivotal Phase 2 TRUST-II study evaluating our investigational precision therapy for ROS1+ NSCLC.

Learn more: shorturl.at/zBCF0

#lcsm

Today we announced positive interim data from our global pivotal Phase 2 TRUST-II study evaluating our investigational precision therapy for ROS1-positive NSCLC.

Learn more here: anhearttherapeutics.com/news/press-rel…

#ESMO23 #lcsm

We’re excited to attend #ESMO23 in Madrid!

We’re looking forward to the opportunity to connect with others in the scientific community as we collectively work to bring new treatment options to people living with cancer.

See you there!

#lcsm

shorturl.at/npHMT

We are excited to announce the appointment of Charlotte Arnold as AnHeart’s Chief Corporate Affairs Officer.

Charlotte will lead communications and investor relations for the company.

Join us in welcoming Charlotte to our team!

anhearttherapeutics.com/news/press-rel…

We recently announced the initiation of a global Phase 2 clinical trial evaluating our mIDH1 inhibitor in IDH1-mutant glioma.

Learn more about the study: shorturl.at/dstEM

We are excited to share that we’ve initiated a global Phase 2 clinical trial evaluating our mIDH1 inhibitor in IDH1-mutant glioma, one of the most common types of adult primary brain cancer.

Learn more: anhearttherapeutics.com/news/press-rel…

The AnHeart team is excited to be at #ASCO2023 , meet us at Booth #5043 to learn more about our work in precision oncology. See you there!

#PrecisionOncology #CancerResearch #ROS1 #LungCancer #Glioma